Rep. Jared Moskowitz Sells Off Shares of Abbott Laboratories (NYSE:ABT)

Representative Jared Moskowitz (D-Florida) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on February 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on January 15th. The trade occurred in the Representative’s “MORGAN STANLEY ACTIVE ASSETS (1)” account.

Representative Jared Moskowitz also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of AbbVie (NYSE:ABBV) on 1/15/2025.
• Purchased $1,001 – $15,000 in shares of McKesson (NYSE:MCK) on 1/15/2025.
• Sold $1,001 – $15,000 in shares of Canadian National Railway (NYSE:CNI) on 1/15/2025.
• Purchased $1,001 – $15,000 in shares of Stryker (NYSE:SYK) on 1/15/2025.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 1/15/2025.
• Sold $1,001 – $15,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 1/15/2025.

Abbott Laboratories Price Performance

Shares of ABT traded up $1.22 during trading hours on Thursday, reaching $131.71. The stock had a trading volume of 1,414,247 shares, compared to its average volume of 6,780,594. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $132.50. The stock has a market capitalization of $228.44 billion, a PE ratio of 17.22, a PEG ratio of 2.39 and a beta of 0.75. The company’s 50-day moving average is $118.34 and its two-hundred day moving average is $115.71.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, meeting the consensus estimate of $1.34. The firm had revenue of $10.97 billion during the quarter, compared to the consensus estimate of $11.03 billion. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The business’s quarterly revenue was up 7.2% on a year-over-year basis. During the same period last year, the company earned $1.19 earnings per share. Research analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be paid a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.79%. The ex-dividend date is Wednesday, January 15th. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.55. Abbott Laboratories’s payout ratio is presently 30.85%.

Insider Activity at Abbott Laboratories

In other news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the completion of the sale, the executive vice president now directly owns 125,697 shares of the company’s stock, valued at $16,152,064.50. This trade represents a 15.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on ABT shares. Piper Sandler upped their price target on shares of Abbott Laboratories from $131.00 to $133.00 and gave the company an “overweight” rating in a research report on Thursday, October 17th. Barclays reaffirmed an “overweight” rating and set a $158.00 target price (up from $149.00) on shares of Abbott Laboratories in a research report on Monday, January 27th. Mizuho lifted their price objective on Abbott Laboratories from $115.00 to $130.00 and gave the stock a “neutral” rating in a research note on Thursday, October 17th. Wells Fargo & Company upped their price target on shares of Abbott Laboratories from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, January 23rd. Finally, StockNews.com downgraded Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Four investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $133.06.

Institutional Trading of Abbott Laboratories

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bernard Wealth Management Corp. acquired a new position in Abbott Laboratories during the 4th quarter valued at about $452,000. German American Bancorp Inc. grew its holdings in Abbott Laboratories by 1.2% during the fourth quarter. German American Bancorp Inc. now owns 85,426 shares of the healthcare product maker’s stock worth $9,663,000 after buying an additional 1,006 shares in the last quarter. Bank of Nova Scotia lifted its stake in Abbott Laboratories by 38.1% during the 4th quarter. Bank of Nova Scotia now owns 351,598 shares of the healthcare product maker’s stock valued at $39,771,000 after acquiring an additional 96,995 shares in the last quarter. Shelton Capital Management boosted its holdings in Abbott Laboratories by 0.7% during the 4th quarter. Shelton Capital Management now owns 23,842 shares of the healthcare product maker’s stock worth $2,697,000 after acquiring an additional 162 shares during the last quarter. Finally, Southeast Asset Advisors LLC grew its stake in shares of Abbott Laboratories by 13.6% in the 4th quarter. Southeast Asset Advisors LLC now owns 9,047 shares of the healthcare product maker’s stock worth $1,023,000 after acquiring an additional 1,082 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

About Representative Moskowitz

Jared Evan Moskowitz (Democratic Party) is a member of the U.S. House, representing Florida’s 23rd Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Moskowitz (Democratic Party) is running for re-election to the U.S. House to represent Florida’s 23rd Congressional District. He declared candidacy for the 2026 election.

Jared Evan Moskowitz was born in Coral Springs, Florida. Moskowitz graduated from Marjory Stoneman Douglas High School. He earned a bachelor’s degree in political science and government from George Washington University in 2003 and a law degree from Nova Southeastern University in 2007. Moskowitz’s career experience includes working as the director of the Florida Division of Emergency Management and general counsel with AshBritt Inc.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.